Results 91 to 100 of about 28,270 (206)

Assessing a 600-mg Loading Dose of Clopidogrel 24 Hours Prior to Pipeline Embolization Device Treatment [PDF]

, 2018
Background: Clopidogrel/aspirin antiplatelet therapy routinely is administered 7-10 days before pipeline aneurysm treatment. Our study assessed the safety and efficacy of a 600-mg loading dose of clopidogrel 24 hours before Pipeline Embolization Device ...
Atallah, MD, Elias, Bekelis, MD, Kimon, Chalouhi, MD, Nohra, Hasan, MD, David, Jabbour, Pascal, MD, Rosenwasser, MD, MBA, FACS, FAHA, Robert H., Saad, MD, Hassan, Smith, MD, Michelle, Tjoumakaris, MD, Stavropoula, Zarzour, MD, Hekmat   +9 more
core   +2 more sources

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity‐Matched Cohort Study

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1547-1554, June 2026.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon, Chen Gurevitz, Tzippy Shochat, Shiri Kushnir, Guy Witberg, Amos Levi, Dan Gilon, Ran Kornowski, Paaladinesh Thavendiranathan, Husam Abdel Qadir, Zaza Iakobishvili   +10 more
wiley   +1 more source

CYP2C19 Polymorphism and Platelet Aggregation‐Associated Risks in Atrial Fibrillation Patients Undergoing PCI

Clinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT CYP2C19 genetic polymorphisms impact the antiplatelet effect of clopidogrel and associate with ischemic and bleeding risk in patients undergoing percutaneous coronary intervention (PCI). This study aimed to evaluate the association of CYP2C19 and platelet reactivity (PR) with these risks, in atrial fibrillation (AF) patients undergoing PCI ...
Diona Gjermeni, Sofia Szabó, Viktoria Anfang, Hannah Vetter, Carina Juelch, Svenja Rademacher, Tian Li, Stefan Leggewie, David Hesselbarth, Daniel Duerschmied, Dietmar Trenk, Dirk Westermann, Christoph B. Olivier   +12 more
wiley   +1 more source

Ticagrelor alters the membrane of Staphylococcus aureus and enhances the activity of vancomycin and daptomycin without eliciting cross-resistance

mBio
Infections with multidrug-resistant bacteria pose a major healthcare problem which urges the need for novel treatment options. Besides its potent antiplatelet properties, ticagrelor has antibacterial activity against Gram-positive bacteria, including ...
Kirsten Leeten, Nicolas Jacques, Lidia Alejo Esquembre, Dana C. Schneider, Jan Straetener, Camilla Henriksen, Lucia Musumeci, Florence Putters, Sofia Melo, Elena Sánchez-López, Martin Giera, Noémie Penoy, Géraldine Piel, Olivier Verlaine, Ana Amoroso, Bernard Joris, Christoph J. Slavetinsky, Eric Goffin, Bernard Pirotte, Dorte Frees, Heike Brötz-Oesterhelt, Patrizio Lancellotti, Cécile Oury   +22 more
doaj   +1 more source

The development of type 2 diabetes amongst sibling pairs in the South‐South region of Nigeria: The effect of genetics, environment and lifestyle

Diabetic Medicine, Volume 43, Issue 6, June 2026.
Abstract Introduction Type 2 diabetes is a complex condition with a multifactorial pathogenesis. The pathogenesis is considered to be polygenic due to complex interactions between genetic/epigenetic and environmental factors. The aim of this study is to determine the genetic, environmental and lifestyle factors associated with the development of type 2
Sunny Chinenye, Ibi Erekosima, Adrian H. Heald, Gesiye Bozimo, Simon G. Anderson, Samuel Seidu, Kariba Akhidue, Adaeze Ugwu, Chioma Unachukwu, Ibitrokoemi Korubo, Kingsley Chukwuemeka Patrick‐Iwuanyanwu, Victoria Gomba, Uwoma Batubo, Victoria Akanatei, Victor Ken‐Uba, Iyeopu Siminialayi, Sokiprim Akoko, Justin Ideozu, Hamilton Opurum   +18 more
wiley   +1 more source

The Prognostic Impact of Multiple Adverse Events on Long‐Term Mortality Following Acute Myocardial Infarction

Catheterization and Cardiovascular Interventions, Volume 107, Issue 6, Page 1651-1659, May 1, 2026.
ABSTRACT Background Adverse events after acute myocardial infarction (AMI) are individually associated with poor outcomes, but the prognostic impact of the overlap of different event types occurring sequentially within the same patient remains uncertain.
Kyung Hoon Roh, Yong Hee Kim, Eun Ho Choo, Kwan Yong Lee, Ik Jun Choi, Jong‐Min Lee, Ki‐Dong Yoo, Mahn‐Won Park, Chul Soo Park, Hee‐Yeol Kim, Min Chul Kim, Youngkeun Ahn, Kiyuk Chang   +12 more
wiley   +1 more source

Ticagrelor – toward more efficient platelet inhibition and beyond

Therapeutics and Clinical Risk Management, 2018
Michał J Kubisa,1 Mateusz P Jezewski,1 Aleksandra Gasecka,2,3 Jolanta M Siller-Matula,4 Marek Postuła1 1Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CEPT), 21st Chair and Department of Cardiology,
Kubisa MJ, Jezewski MP, Gasecka A, Siller-Matula JM, Postuła M   +4 more
doaj  

Emerging Roles of Adenosine Metabolism in Astrocytes During Brain Injury

CNS Neuroscience &Therapeutics, Volume 32, Issue 5, May 2026.
Adenosine, as a key metabolic and neurotransmitter in the brain, has become an important therapeutic target for improving the efficacy of immunotherapy for stroke. However, gaps in knowledge about its metabolic pathways have become a key factor limiting its clinical translation.
Shu Zhu, Shanshan Zhong, Xiaoru Lin, Chuansheng Zhao, Yugang Li   +4 more
wiley   +1 more source

Quantification of unbound concentration of ticagrelor in plasma as a proof of mechanism biomarker of the reversal agent, MEDI2452.

PLoS ONE, 2018
Ticagrelor, a P2Y12 antagonist, is approved for prevention of thromboembolic events. MEDI2452 is a potential reversal agent for ticagrelor and ticagrelor active metabolite (TAM). The total plasma exposure of ticagrelor and TAM in patients are roughly 0.5-
Ann-Sofie Sandinge, Annika Janefeldt, Susanne Pehrsson, Sven Nylander   +3 more
doaj   +1 more source

Prolonged dual anti-platelet therapy in stable coronary disease: a comparative observational study of benefits and harms in unselected versus trial populations [PDF]

, 2016
Objective: To estimate the potential magnitude in unselected patients of the benefits and harms of prolonged dual antiplatelet therapy after acute myocardial infarction seen in selected patients with high risk characteristics in trials.
Chung, SC, Denaxas, S, Emmas, C, Hemmingway, H, Moayyeri, A, Pasea, L, Pujades Rodriguez, MDM, Rapsomaniki, E, Shah, AD, Stogiannis, D, Timmis, A   +10 more
core   +2 more sources